PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval for MuGard in Korea Print E-mail
Tuesday, 31 March 2015 10:56
DALLAS and NEW YORK--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company advancing protein biologic therapies and oncology supportive care products, announced today that its Korean marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: 128940) has received marketing approval in Korea from the country's Ministry of Food and Drug Safety ("MFDS") and the Korea Testing & Research Institute (KTR) for MuGard, its oncology supportive-care treatment for the management of oral mucositis.
Read more...
 
Actinium Pharmaceuticals Opens Enrollment for the Fourth and Final Cohort in the Company’s Ongoing Phase I/II Trial in Acute Myeloid Leukemia Print E-mail
Tuesday, 24 March 2015 07:56
NEW YORK, NY – March 24, 2015 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the Company’s investigational new drug Actimab-A at a higher activity level of 2.0 μCi/kg per dose. 
Read more...
 
Actinium Pharmaceuticals Opens Enrollment for the Fourth and Final Cohort in the Company’s Ongoing Phase I/II Trial in Acute Myeloid Leukemia Print E-mail
Tuesday, 24 March 2015 07:56
NEW YORK, NY – March 24, 2015 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses 4 to 7 days apart of the Company’s investigational new drug Actimab-A at a higher activity level of 2.0 μCi/kg per dose. 
Read more...
 
CEL-SCI REPORTS 2nd CONSECUTIVE MONTH OF RECORD PATIENT ENROLLMENT IN 2015 FOR ITS PHASE III HEAD AND Print E-mail
Tuesday, 03 March 2015 11:56
Vienna, VA--CEL-SCI Corporation (NYSE MKT: CVM) today announced that in February it has enrolled 25 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
Read more...
 
Pluristem and

Error. Page cannot be displayed. Please contact your service provider for more details. (19)

Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation
Print E-mail
Tuesday, 03 March 2015 11:35
 HAIFA, ISRAEL, March 3, 2015 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI) TASE: PLTR), a leading developer of placenta-based cell therapy products, announced today strong positive data from a preclinical study of PLX-R18 cells to improve outcomes of bone marrow transplantation.
Read more...
 
Provectus Biopharmaceuticals Will Hold Its 2014 Year-End Quarterly Business Update Conference Call at 4 PM Eastern, Thursday, March 12, 2015 Print E-mail
Tuesday, 24 February 2015 22:20
KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will hold its year-end quarterly business update conference call at 4 pm Eastern Daylight Time, on Thursday, March 12, 2015.
Read more...
 
Provectus Biopharmaceuticals Will Present at 8th Annual European Life Science CEO Forum & Exhibition Print E-mail
Wednesday, 18 February 2015 19:39
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will present at the 8th Annual European Life Science CEO Forum & Exhibition. Peter Culpepper, CFO and COO, will present on March 3, 2015, at 3:15 pm local time.
Read more...
 
Significant Findings in U.S. National Institutes of Health's Trial of Pluristem's PLX-R18 Cells for Treatment of Acute Radiation Syndrome Print E-mail
Wednesday, 18 February 2015 08:50
HAIFA, Israel--Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today the positive results of a recently completed trial conducted by the U.S. National Institutes of Health (NIH) to evaluate PLX-R18 cells to treat bone marrow damaged by exposure to high levels of radiation, such as can occur after a nuclear disaster.
Read more...
 
Late Melanoma Patients Will Need Several Lines of Therapy, Intralesional Treatment Promising Says New Paper Print E-mail
Thursday, 12 February 2015 16:31
Newswise –February 12, 2015- Despite advances in melanoma treatment, many patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma will need several lines of therapy according to a recent paper in Current Opinion in Oncology.
Read more...
 
The Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment in Its Phase III Head and Neck Cancer Trial Print E-mail
Wednesday, 11 February 2015 20:14
VIENNA, Va.--CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Philippines Regulatory Agency (PFDA) has cleared the Company to commence patient enrollment of the Phase III head and neck cancer trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) in the Philippines.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 12
BMR:1